Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Oncology
Erschienen in: Current Treatment Options in Oncology 11/2023

16.10.2023

Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review

verfasst von: Tarek Assi, MD, Carine Ngo, MD, PHD, Matthieu Faron, MD, PHD, Benjamin Verret, MD, PHD, Antonin Lévy, MD, Charles Honoré, MD, PHD, Clémence Hénon, MD, PHD, Cécile Le Péchoux, MD, Rastilav Bahleda, MD, Axel Le Cesne, MD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Opinion statement

The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear recommendations or specific guidelines. In the advanced setting, specific systemic therapy such as eribulin and trabectedin showed promising activity in comparison to conventional therapy (doxorubicin- and gemcitabine-based protocols), which currently remains the current standard of care at initial stages of the disease. The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach.
Literatur
1.
Fletcher CDM, Bridge JA, Hogendoorn PCW. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013.
2.
3.
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.
4.
Fletcher CD. The evolving classification of soft tissue tumours–an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11.PubMedCrossRef
5.
Enzinger FM, Winslow DJ. Liposarcoma. Virchows Archiv. 1962;335(4):367–88.CrossRef
6.
Manji GA, Schwartz GK. Managing liposarcomas: cutting through the fat. J Oncol Pract. 2016;12(3):221–7.PubMedCrossRef
7.
Rudzinski E, Mawn L, Kuttesch J, Wushensky C, Wills M. Orbital pleomorphic liposarcoma in an eight-year-old boy. Pediatr Dev Pathol. 2011;14(4):339–44.PubMedCrossRef
8.
Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011;117(23):5359–69.PubMedCrossRef
9.
Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002;26(5):601–16.PubMedCrossRef
10.
Tandon B, Hagemann IS, Maluf HM, Pfeifer JD, Al-Kateb H. Association of Li-Fraumeni syndrome with small cell carcinoma of the ovary, hypercalcemic type and concurrent pleomorphic liposarcoma of the cervix. Int J Gynecol Pathol. 2017;36(6):593–9.PubMedCrossRef
11.
Italiano A, Garbay D, Cioffi A, Maki RG, Bui B. Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Ann Oncol. 2012;23(8):2205–6.PubMedCrossRef
12.
Toulmonde M, Italiano A, Penel N, Cioffi A, Le Cesne A, Isambert N, et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. J Clin Oncol. 2011;29(15_suppl):10071–10071.CrossRef
13.
• Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–65. Most recent recommendations for the management of soft tissue sarcomas.PubMedCrossRef
14.
Casali PG, Bruzzi P, Bogaerts J, Blay JY, Panel RCE (RCE) C. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol. 2014;26(2):300–6.PubMedPubMedCentralCrossRef
15.
Frezza AM, Jones RL, Vullo SL, Asano N, Lucibello F, Ben-Ami E, et al. Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series. JAMA Oncol. 2018;4(9):e180219–e180219.PubMedPubMedCentralCrossRef
16.
Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, et al. Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020;126(1):98–104.PubMedCrossRef
17.
• Smrke A, Frezza AM, Giani C, Somaiah N, Brahmi M, Czarnecka AM, et al. Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network. ESMO open. 2022;7(3): 100522. International multicentric retrospective data on one of the most rare STS histotypes, clear cell sarcoma, assessing the role of current systemic therapies.PubMedPubMedCentralCrossRef
18.
Hornick JL. Subclassification of pleomorphic sarcomas: how and why should we care? Ann Diagn Pathol. 2018;37:118–24.PubMedCrossRef
19.
Miettinen M, Enzinger FM. Epithelioid variant of pleomorphic liposarcoma: a study of 12 cases of a distinctive variant of high-grade liposarcoma. Mod Pathol. 1999;12(7):722–8.PubMed
20.
Anderson WJ, Jo VY. Pleomorphic liposarcoma: updates and current differential diagnosis. Seminars in diagnostic pathology. WB Saunders; 2019;36(2).
21.
Creytens D, Folpe AL, Koelsche C, Mentzel T, Ferdinande L, van Gorp JM, et al. Myxoid pleomorphic liposarcoma—a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma. Mod Pathol. 2021;34(11):2043–9.PubMedCrossRef
22.
Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet août. 2010;42(8):715–21.CrossRef
23.
Idbaih A, Coindre JM, Derré J, Mariani O, Terrier P, Ranchère D, et al. Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest. 2005;85(2):176–81.PubMedCrossRef
24.
Sugita S, Seki K, Yokozawa K, Tochigi N, Furuta K, Hisaoka M, et al. Analysis of CHOP rearrangement in pleomorphic liposarcomas using fluorescence in situ hybridization. Cancer Sci. 2009;100(1):82–7.PubMedCrossRef
25.
Lee JC, Jeng YM, Liau JY, Tsai JH, Hsu HH, Yang CY. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. Mod Pathol. 2015;28(8):1064–73.PubMedCrossRef
26.
Mariño-Enríquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopathol. 2014;122(2):128–37.PubMedCrossRef
27.
28.
Ciliberti V, Cretella P, Zeppa P, Caputo A. Pleomorphic liposarcoma with liver metastasis diagnosed by combined fine-needle aspiration cytology and core-needle biopsy. Diagn Cytopathol. 2022;50(1):E28-31.PubMedCrossRef
29.
Apostolou G, Biteli M, Chatzipantelis P. Cytopathological diagnosis of metastatic pleomorphic liposarcoma in the lung: a report of a case correlated with the histopathology of the primary tumour. Diagn Cytopathol. 2009;37(9):667–70.PubMedCrossRef
30.
Dodd LG, Jiang X, Rao K, Bui MM. Pleomorphic liposarcoma: a cytologic study of five cases. Diagn Cytopathol. 2015;43(2):138–43.PubMedCrossRef
31.
Wakely PE Jr, Wangsiricharoen S, Ali SZ. Pleomorphic liposarcoma: a clinicopathologic study of 20 FNA cases. Cancer Cytopathol. 2022;130:705–13.PubMedCrossRef
32.
May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, et al. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer. 2015;15(1):1–12.CrossRef
33.
Valenciaga A, Iwenofu OH, Tinoco G. Larotrectinib in a patient with advanced pleomorphic liposarcoma of the uterus. J Natl Compr Canc Netw. 2021;19(7):775–9.PubMedCrossRef
34.
Friedman JL, Bistritz JI, Robinson MJ. Pleomorphic liposarcoma of the pterygomandibular space involving the maxilla. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 1995;79(4):488–91.CrossRef
35.
Agarwal J, Kadakia S, Agaimy A, Ogadzanov A, Khorsandi A, Chai RL. Pleomorphic liposarcoma of the head and neck: presentation of two cases and literature review. Am J Otolaryngol. 2017;38(4):505–7.PubMedCrossRef
36.
Wang JG, Wei ZM, Liu H, Li YJ. Primary pleomorphic liposarcoma of pericardium. Interact Cardiovasc Thorac Surg. 2010;11(3):325–7.PubMedCrossRef
37.
Tan NY, Najam M, Lyle MA, Maleszewski JJ, Collins JD, Klarich KW. Dramatic presentation of cardiac pleomorphic liposarcoma. Circulation: Cardiovasc Imaging. 2021;14(8):e012620.
38.
Ganesan S, Moorthy N, Venkataraman SK, Mahipathy SRRV, Sundaramurthy N. Giant pleomorphic liposarcoma of anterior chest wall. JK Sci J Med Educ Res. 2022;24(2):140–2.
39.
Kim MJ, Koo HL, Jun SY, Ro JY. Pleomorphic liposarcoma of the kidney: a case report. Kor J Pathol. 2003;37(3):210–3.
40.
Dey T, Khosla D, Kumar D, Chatterjee D, Madan R, Singh H, et al. Rare case of primary pulmonary pleomorphic liposarcoma treated with multimodal therapy. Ochsner J. 2021;21(4):431–5.PubMedPubMedCentralCrossRef
41.
Verdugo D, Voltaggio L, Hoot A, Rodriguez FJ. Cerebral pleomorphic liposarcoma: clinicopathologic findings. Clin Neuropathol. 2019;38(5):233.PubMedCrossRef
42.
Tiemeier GL, Brown JM, Pratap SE, McCarthy C, Kastrenopoulou A, Bradley K, et al. Pleomorphic liposarcoma of bone: a rare primary malignant bone tumour. Clin Sarcoma Res. 2018;8(1):1–9.CrossRef
43.
Torigoe T, Matsumoto T, Terakado A, Takase M, Yamasaki S, Kurosawa H. Primary pleomorphic liposarcoma of bone: MRI findings and review of the literature. Skelet Radiol. 2006;35(7):536–8.CrossRef
44.
Jo SJ, Jung HK, Nam KH. Recurrent primary pleomorphic liposarcoma of the breast: a case report with imaging findings. J Breast Cancer. 2020;23(5):567.PubMedPubMedCentralCrossRef
45.
Gardner JM, Dandekar M, Thomas D, Goldblum JR, Weiss SW, Billings SD, et al. Cutaneous and subcutaneous pleomorphic liposarcoma: a clinicopathologic study of 29 cases with evaluation of: MDM2: gene amplification in 26. Am J Surg Pathol. 2012;36(7):1047–51.PubMedCrossRef
46.
Pawel BR, de Chadarevian JP, Inniss S, Kalwinski P. Mesenteric pleomorphic liposarcoma in an adolescent. Arch Pathol Lab Med. 1997;121(2):173.PubMed
47.
Levine PH, Wei XJ, Gagner JP, Flax H, Mittal K, Blank SV. Pleomorphic liposarcoma of the uterus: case report and literature review. Int J Gynecol Pathol. 2003;22(4):407–11.PubMedCrossRef
48.
Yozu M, Symmans P, Dray M, Griffin J, Han C, Ng D, et al. Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field. Virchows Arch. 2013;462(3):355–60.PubMedCrossRef
49.
Orosz Z, Rohonyi B, Luksander A, Szántó J. Pleomorphic liposarcoma of a young woman following radiotherapy for epithelioid sarcoma. Pathol Oncol Res. 2000;6(4):287–91.PubMedCrossRef
50.
Arbabi L, Warhol MJ. Pleomorphic liposarcoma following radiotherapy for breast carcinoma. Cancer. 1982;49(5):878–80.PubMedCrossRef
51.
Lee HG, Aurit S, Silberstein P, Gootee J. Primary anatomical site as a prognostic factor for pleomorphic liposarcoma. J Cancer Res Clin Oncol. 2020;146(6):1501–8.PubMedCrossRef
52.
Wan L, Tu C, Qi L, Li Z. Survivorship and prognostic factors for pleomorphic liposarcoma: a population-based study. J Orthop Surg Res. 2021;16(1):1–10.
53.
Downes KA, Goldblum JR, Montgomery EA, Fisher C. Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases. Mod Pathol. 2001;14(3):179–84.PubMedCrossRef
54.
55.
Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, et al. Myxoid/round cell and pleomorphic liposarcomas. Cancer. 2007;109(12):2522–31.PubMedCrossRef
56.
Muratori F, Frenos F, Bettini L, Matera D, Mondanelli N, Scorianz M, et al. Liposarcoma: clinico-pathological analysis, prognostic factors and survival in a series of 307 patients treated at a single institution. J Orthop Sci. 2018;23(6):1038–44.PubMedCrossRef
57.
Hornick JL, Bosenberg MW, Mentzel T, McMenamin ME, Oliveira AM, Fletcher CD. Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol. 2004;28(10):1257–67.PubMedCrossRef
58.
Wang L, Ren W, Zhou X, Sheng W, Wang J. Pleomorphic liposarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic study of 32 additional cases. Pathol Int. 2013;63(11):523–31.PubMedCrossRef
59.
Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41(18):2853–60.PubMedCrossRef
60.
• Assi TS, Honoré C, Bahleda R, Henon C, Verret B, Faron M, et al. 48MO Characteristics and outcomes of 76 patients with pleomorphic liposarcoma: the Gustave Roussy experience. ESMO Open. 2023;8(1): 101085. Retrospective data collection of pleomorphic liposarcoma to assess the role of current systemic approaches in the advanced setting.
61.
62.
63.
Cortes J, Schöffski P, Littlefield BA. Multiple modes of action of eribulin mesylate: emerging data and clinical implications. Cancer Treat Rev. 2018;70:190–8.PubMedCrossRef
64.
Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017;35(30):3433–9.PubMedCrossRef
65.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–37.PubMedCrossRef
66.
Chen TWW, Hsu CL, Hong RL, Lee JC, Chang K, Yu CW, et al. A single-arm phase Ib/II study of lenvatinib plus eribulin in advanced liposarcoma and leiomyosarcoma. Clin Cancer Res. 2022;28(23):5058–65.PubMedCrossRef
67.
Kim CG, Sim NS, Kim JE, Yun KH, Lee YH, Kim SH, et al. Phase II clinical trial of eribulin–gemcitabine combination therapy in previously treated patients with advanced liposarcoma or leiomyosarcoma. Clin Cancer Res. 2022;28(15):3225–34.PubMedCrossRef
68.
Kobayashi E, Naito Y, Asano N, Maejima A, Endo M, Takahashi S, et al. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol. 2019;49(10):938–46.PubMedPubMedCentralCrossRef
69.
Escudero J, Heredia-Soto V, Wang Y, Ruiz P, Hu Y, Gallego A, et al. Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect? Cancer Cell Int. 2021;21:646.PubMedPubMedCentralCrossRef
70.
Assi T, Kattan J, El Rassy E, Honore C, Dumont S, Mir O, et al. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. Cancer Treat Rev. 2019;72:37–44.PubMedCrossRef
71.
Demetri GD, Chawla SP, Von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188–96.PubMedCrossRef
72.
Cesne AL, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, et al. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol. 2021;32(8):1034–44.PubMedCrossRef
73.
74.
Demetri GD, Von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786.PubMedCrossRef
75.
Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019;125(15):2610–20.PubMedCrossRef
76.
Kiyuna T, Tome Y, Murakami T, Kawaguchi K, Igarashi K, Miyake K, et al. Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. BMC Cancer. 2018;18(1):1–8.CrossRef
77.
Chaigneau L, Jary M, Nerich V, Hervieu A, Aubry S, Barra CC, et al. Real-world experience of efficacy and safety of trabectedin in patients with soft tissue sarcoma: a bicentric retrospective analysis. Oncology. 2022;100(12):633–44.PubMedCrossRef
78.
Schuler MK, Richter S, Platzek I, Beuthien-Baumann B, Wieczorek K, Hamann C, et al. Trabectedin in the neoadjuvant treatment of high-grade pleomorphic sarcoma: report of a rare case and literature review. Case Rep Oncol Med. 2013;2013:1–5.
79.
Wagner MJ, Zhang Y, Cranmer LD, Loggers ET, Black G, McDonnell S, et al. A phase 1/2 trial combining avelumab and trabectedin for advanced liposarcoma and leiomyosarcoma. Clin Cancer Res. 2022;28(11):2306–12.
80.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.PubMedCrossRef
81.
Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016;34(32):3898–905.PubMedCrossRef
82.
Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18(8):1089–103.PubMedPubMedCentralCrossRef
83.
84.
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–410.PubMedPubMedCentralCrossRef
85.
D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26.PubMedPubMedCentralCrossRef
86.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501.PubMedPubMedCentralCrossRef
87.
Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93–7.PubMedCrossRef
88.
Burgess MA, Bolejack V, Schuetze S, Van Tine BA, Attia S, Riedel RF, et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): final results of SARC028 expansion cohorts. J Clin Oncol. 2019;11015.
89.
Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, et al. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res. 2013;19(17):4843–53.PubMedCrossRef
90.
Digklia A, Coukos G, Homicsko K. Trabectedin and durvalumab combination is feasible-and active in relapsing ovarian cancer. Clin Cancer Res. 2022; 28(9):1745–7.
91.
Wilky BA, Trucco MM, Kolonias D, Wieder E, Subhawong T, Rosenberg A, et al. A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). American Society of Clinical Oncology. 2018;11547.
92.
93.
van der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.PubMedCrossRef
94.
Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.PubMedCrossRef
95.
Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, et al. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer. 2017;123(23):4640–7.PubMedCrossRef
96.
Valverde CM, Martin Broto J, Lopez-Martin JA, Romagosa C, Sancho Marquez MP, Carrasco JA, et al. Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study—NCT01692496. Am Soc Clin Oncol. 2016:11039.
97.
Chamberlain FE, Wilding C, Jones RL, Huang P. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opin Investig Drugs. 2019;28(6):505–11.PubMedCrossRef
98.
Nakamura T, Matsumine A, Kawai A, Araki N, Goto T, Yonemoto T, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–16.PubMedCrossRef
99.
Seto T, Song MN, Trieu M, Yu J, Sidhu M, Liu CM, et al. Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California. Med Sci. 2019;7(3):48.
100.
Schöffski P. Established and experimental systemic treatment options for advanced liposarcoma. Oncol Res Treatment. 2022;45(9):525–43.CrossRef
101.
Assi T, Kattan J, Rassy E, Nassereddine H, Farhat F, Honore C, et al. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: a comprehensive review. Crit Rev Oncol/Hematol. 2020;153:103029.PubMedCrossRef
102.
103.
104.
Kiyuna T, Murakami T, Tome Y, Igarashi K, Kawaguchi K, Miyake K, et al. Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. Tissue Cell. 2018;53:30–6.PubMedCrossRef
105.
Fu X, Niu W, Li J, Kiliti AJ, Al-Ahmadie HA, Iyer G, et al. Activating mutation of PDGFRB gene in a rare cardiac undifferentiated intimal sarcoma of the left atrium: a case report. Oncotarget. 2017;8(46):81709.PubMedPubMedCentralCrossRef
106.
Kiyuna T, Tome Y, Murakami T, Zhao M, Miyake K, Igarashi K, et al. Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. J Cell Biochem. 2018;119(9):7827–33.PubMedPubMedCentralCrossRef
Metadaten
Titel
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review
verfasst von
Tarek Assi, MD
Carine Ngo, MD, PHD
Matthieu Faron, MD, PHD
Benjamin Verret, MD, PHD
Antonin Lévy, MD
Charles Honoré, MD, PHD
Clémence Hénon, MD, PHD
Cécile Le Péchoux, MD
Rastilav Bahleda, MD
Axel Le Cesne, MD
Publikationsdatum
16.10.2023
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 11/2023
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01139-3

Weitere Artikel der Ausgabe 11/2023

Current Treatment Options in Oncology 11/2023 Zur Ausgabe

ReviewPaper

Optimal Therapeutic Strategy for PD-L1 Negative Metastatic Non-Small Cell Lung Cancer: A Decision-Making Guide Based on Clinicopathological and Molecular Features

ReviewPaper

Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy

ReviewPaper

Sequencing Systemic Therapy in Hepatocellular Carcinoma

ReviewPaper

Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

Correction

Correction to: Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond

ReviewPaper

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise